SAN DIEGO, May 3, 2012 /PRNewswire/ -- Gen-Probe
Incorporated (NASDAQ: GPRO) announced today that the Company has
withdrawn from the following three upcoming investor conferences
previously announced on April 26,
2012, and therefore will not webcast presentations at any of
these investor conferences:
- Deutsche Bank 37th Annual Health Care Conference in
Boston on May 8 at 1:30 p.m. Eastern
Time;
- Baird's 2012 Growth Stock Conference in Chicago on May 9
at 3:40 p.m. Central Time; and
- Bank of America Merrill Lynch 2012 Health Care Conference in
Las Vegas on May 15 at 4:20 p.m.
Pacific Time.
(Logo:
http://photos.prnewswire.com/prnh/20120312/LA68580LOGO)
About Gen-Probe
Gen-Probe is a global leader in the development,
manufacture and marketing of rapid, accurate and cost-effective
molecular diagnostic products and services that are used primarily
to diagnose human diseases, screen donated human blood, and ensure
transplant compatibility. Gen-Probe is headquartered in
San Diego and employs
approximately 1,400 people. For more information, go to
http://www.gen-probe.com.
Caution Regarding Forward-Looking Statements
Any statements in this press release about our
expectations, beliefs, plans, objectives, assumptions, or future
events or performance are not historical facts and are
forward-looking statements. Forward-looking statements are
not guarantees of performance. They involve known and unknown
risks, uncertainties and assumptions that may cause actual results
to differ materially from those expressed or implied. For
information about risks and uncertainties we face and a discussion
of our financial statements and footnotes, see documents we have
filed with the SEC, including our most recent Form 10-K, and all
subsequent periodic filings. We assume no obligation and
expressly disclaim any duty to update any forward-looking statement
to reflect events or circumstances after the date of this press
release or to reflect the occurrence of unanticipated events.
Contact:
Paula Izidoro
Investor Relations
858-410-8904
SOURCE Gen-Probe Incorporated